Frank I. Scott, MD, MSCE, is an expert in inflammatory bowel disease, with a particular interest in the risk-benefit balance of biologic and immunosuppressive therapies in Crohn's disease and ulcerative colitis. Dr. Scott received his undergraduate degree from the University of Pennsylvania and medical degree from Temple University in Philadelphia. After completing his internal medicine residency at Weill Cornell Medical Center, Dr. Scott returned to Philadelphia for his gastroenterology fellowship at the University of Pennsylvania, also completing an advanced fellowship in inflammatory bowel diseases in 2013 as well as a Masters' of Science in Clinical Epidemiology (MSCE). After several years on faculty at the University of Pennsylvania, Dr. Scott joined the faculty at the University of Colorado in Denver, Colorado in 2016.
Dr. Scott is heavily invested in pharmacoepidemiologic research. His primary research interests include using quantitative and simulation-based methods to better understand the risk benefit balance and medication positioning in inflammatory bowel disease and how to best optimize the use of current therapies while reducing delays in care. He is also interested in exploring rare drug effects such as the association between antibiotic use and pediatric-onset obesity, and how the anti-fibrotic properties of HMG-coA reductase inhibitors, i.e. statins, may reduce the rates of adhesion-related and fibrostenotic complications after intra-abdominal surgery. He has significant experience in epidemiologic methods including decision analyses, Markov modeling, cost-effectiveness analysis, study design using large secondary and EMR-derived data, and disease risk and propensity score adjustment in such data. Over the course of his career, he has led or collaborated on research funded by the NIH, Crohn’s and Colitis Foundation, PCORI, and multiple industry partners.